YCN Thyroid NSSG. *** VALID ON DATE OF PRINTING ONLY - all guidelines available at *** page 1 of 8 version number: 1.

Similar documents
Gerard M. Doherty, MD

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

1. Protocol Summary Summary of Trial Design. IoN

Dynamic Risk Stratification:

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Current Issues in Thyroid Cancer Surgery in 2017

New York, the nation s thyroid gland. Christopher Morley ( ), "Shore Leave"

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

WTC 2013 Panel Discussion: Minimal disease

Thyroid and Adrenal Gland

Risk Adapted Follow-Up

Differentiated Thyroid Carcinoma

Pathology of the Thyroid

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

Differentiated Thyroid Cancer: Initial Management

How Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017

Head & Neck Cancer Network Site Specific Group. Clinical Guidelines. August 2015

Long Term Follow-Up for Differentiated Thyroid Cancer: The Mayo Experience

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

Minimalistic Initial Therapy Options For Low Risk Papillary Thyroid Cancer

Persistent & Recurrent Differentiated Thyroid Cancer

Clinical Guidance in Thyroid Cancers. Stephen Robinson Imperial at St Mary s On behalf of BTA

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

PEDIATRIC Ariel Katz MD

Locally advanced papillary thyroid cancer

131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans

THYROID CANCER IN CHILDREN

An Alphabet Soup of Thyroid Neoplasms

Reoperative central neck surgery

NIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

Management of Thyroid Nodules

What s an NIFTP? Keeping Up To Date in Thyroid 2018

Adjuvant therapy for thyroid cancer

Review Article Management of papillary and follicular (differentiated) thyroid carcinoma-an update

Review Article Management of thyroid carcinoma Alauddin M, Joarder AH

Thyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect

Management of Recurrent Thyroid Cancer

Review Article Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma

Thyroid and Parathyroid Surgery

Papillary Thyroid Microcarcinoma Presenting as Horner s Syndrome: A Novel Clinical Presentation

Follicular Derived Thyroid Tumors

Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD

Preoperative Evaluation

Research Article Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Introduction. Materials and methods Y-N XU 1,2, J-D WANG 1,2

Thyroid Surgery: Lobectomy, total thyroidectomy, LN biopsies or only watchful waiting?

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Disclosures Nodal Management in Differentiated Thyroid Carcinoma

Dilemmas in Cytopathology and Histopathology

40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016

ORIGINAL ARTICLE. Follicular Variant of Papillary Thyroid Carcinoma

Thyroid carcinoma. Assoc. prof. V. Marković, MD, PhD Assoc. prof. A. Punda, MD, PhD D. Brdar, MD, nucl. med. spec.

Changing trends in the management of well-differentiated thyroid carcinoma in Korea

Dr J K Jekel Dept. Surgery University of Pretoria

PEDIATRIC THYROID MALIGNACY

3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women

Thyroid INTRODUCTION ANATOMY SUMMARY OF CHANGES

Volume 2 Issue ISSN

2015 ATA Thyroid Nodule and DTC Guidelines: Perspectives from the Chair What were you thinking????

Research Article Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients

Managing Thyroid Microcarcinomas

Setting The setting was secondary care. The economic study was conducted in the USA.

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

TBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms

Shifting Paradigms and Debates in the Management of Well-differentiated Thyroid Cancer

Initial surgery for differentiated thyroid cancer: What is the appropriate extent and attendant risks and benefits?

Correspondence should be addressed to Giampaolo Papi;

Case Scenario 1: Thyroid

10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary

Thyroid and Parathyroid Disease. RTC Conference Christina Edwards Bailey Faculty: Dr. Carmen Solorzano April 2, 2010

Key Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do?

I treatment for differentiated thyroid carcinoma Current guidelines

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP

Multi-Organ Distant Metastases in Follicular Thyroid Cancer- Rare Case Report

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Ini7al Staging of Follicular Cell-derived Thyroid Cancers: the ATA 2015 IRS and AJCC 8th Ed. Cancer Staging Systems

FACULTY OF MEDICINE Active surveillance as the initial treatment of papillary thyroid microcarcinoma: a 10-years multicentric prospective study

Hope. Healing. Offering. Cancer Treatment Center for Southern Kentucky and Barren River Regional Cancer Center. Cancer Program Annual Report 2011

The role of prophylactic central compartment lymph node dissection in differentiated thyroid carcinoma

Multidisciplinary Care for Well-Differentiated Thyroid Cancer

34 year-old Female with Thyroid Cancer

Outcome of papillary thyroid microcarcinoma: Study of 1,990 cases

Mandana Moosavi 1 and Stuart Kreisman Background

COME HOME Innovative Oncology Business Solutions, Inc.

Clinical Study Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV

Radiation Therapy for Thyroid Cancer. When is Radiation Therapy indicated in Thyroid Cancer of Follicular or Parafollicular Cell Origin?

A Review of Differentiated Thyroid Cancer

The use of Radioactive Iodine (RAI) for Differentiated Thyroid Cancer

Surgical Management of Differentiated Thyroid Cancer

Reference No: Author(s) Approval date: October committee. September Operational Date: Review:

ONLINE CONTINUING EDUCATION ACTIVITY

Transcription:

YCN Thyroid NSSG Guidelines on Indications for Thyroid Surgery, Prophylactic Level 6 and Radioiodine plus follow-up of low risk differentiated thyroid cancer page 1 of 8

i Document Control Title Author(s) Owner Guidelines on Indications for Thyroid Surgery, Prophylactic Level 6 and Radioiodine plus follow-up of low risk differentiated thyroid cancer (Summary of BTA 2014 Guidelines) Dr G Gerrard, Dr V Gill, Mr A Nicolaides YCN Thyroid NSSG Version Control Version/ Draft Date Revision summary 1.0 March 2015 Final first version Contributors to current version Contributor Author/Editor Section/Contribution Dr G Gerrard Dr V Gill Mr A Nicolaides Dr G Gerrard Dr V Gill Mr A Nicolaides All page 2 of 8

ii Information Reader Box Title Author(s) Guidelines on Indications for Thyroid Surgery, Prophylactic Level 6 and Radioiodine plus follow-up of low risk differentiated thyroid cancer (Summary of BTA 2014 Guidelines) Dr G Gerrard, Dr V Gill, Mr A Nicolaides Publication date March 2015 Review date March 2017 Proposed Target Audience for Consultation / Final Statement All consultations and e-mail notification of updated guidelines from the YCN Thyroid NSSG will be consulted to: YCN Thyroid NSSG Proposed Circulation List for Final Statement Contact details All YCN Thyroid Group guidelines will be made available electronically at http://www.ycn.nhs.uk. No hard copies will be circulated by the Group. Yorkshire Cancer Network Level 6 Bexley Wing St James s Institute of Oncology Beckett Street Leeds LS9 7TF info@ycn.nhs.uk 0113 2068087 page 3 of 8

iii Table of Contents I DOCUMENT CONTROL... 2 II INFORMATION READER BOX... 3 III TABLE OF CONTENTS... 4 1 INTRODUCTIONS... 5 2 WHAT SURGERY TO DO IF FNAC IS THY5 / PTC?:... 5 3 WHO NEEDS COMPLETION THYROIDECTOMY AFTER DIAGNOSTIC LOBECTOMY? 5 3.1 PAPILLARY MICROCARCINOMA (CANCER OF 10MM OR LESS)... 5 3.2 PAPILLARY THYROID CANCER ( > 10MM)... 5 3.3 FOLLICULAR THYROID CANCER... 6 3.4 MINIMALLY INVASIVE FTC... 6 3.5 HURTHLE CELL TUMOURS... 6 4 WHEN TO RECOMMEND A LEVEL 6 PROPHYLACTIC CENTRAL COMPARTMENT LN DISSECTION:... 7 5 WHAT FOLLOW-UP IS NEEDED IF NO COMPLETION AFTER LOBECTOMY?... 7 6 WHO NEEDS RADIOIODINE AFTER THYROIDECTOMY?... 8 6.1 PAPILLARY THYROID CANCER... 8 6.2 FOLLICULAR THYROID CANCER... 8 6.3 HURTHLE CELL... 8 page 4 of 8

1 Introductions There are no RCTs & the evidence is weak so consider the risks & benefits of treatment for each patient depending on risk factors present & other variables 2 What surgery to do if FNAC is Thy5 / PTC?: Diagnostic lobectomy: If US suggests <4cm size tumour and no other concerning features. Total thyroidectomy: if: - > 4cm - Multifocal/ Bilateral - Extrathyroidal extension- if possible to see on US - Involved lymph nodes 3 Who needs completion thyroidectomy after diagnostic lobectomy? 3.1 Papillary microcarcinoma (cancer of 10mm or less) multifocal and involving both lobes (on US) Extrathyroidal extension LNs involved family history unfavourable histology discovered by PET (PET positive) 3.2 Papillary thyroid cancer ( > 10mm) Tumour > 4cm in size Or any size and multifocal or bilateral Extrathyroidal extension (pt3 or pt4) Node positive Family history Unfavourable histopath ( tall cell/ columnar/ diffuse sclerosing/ poorly differentiated) Metastatic disease page 5 of 8

1-4 cm Vascular invasion in medium/ big vessels (but evidence unclear - MDT review/discuss) >45years old: Personalised decision making Any age: < 2cm no other risk factors- probably no further surgery >45yrs: 2-4cm- patient discussion 3.3 Follicular thyroid cancer Tumour >4cm in size 1-4cm in size and any of: patient >45yrs Widely invasive Mets- LN or distant Vascular invasion in medium/ big vessels Extrathyroidal extension 3.4 Minimally invasive FTC >4cm Any size and vascular invasion >45yrs- personalised decision making if 2 4cm (& no vascular invasion) 3.5 Hurthle cell tumours > 1cm in size (consider if anything unusual when <1cm) page 6 of 8

4 When to recommend a level 6 prophylactic central compartment LN dissection: (I.e. no clinical or radiological evidence of disease in level 6). Personalised decision making. Consider if have: adverse histological subtype Tumour >4cm in size Extrathyroidal extension Patient > 45 years old 5 What Follow-up is needed if no completion after lobectomy? a) Tumour equal to or <1cm: No follow-up if initial neck US OK Target TSH: low normal if patient needs thyroxine. GP to check TSH annually-risk of hypothyroidism b) Tumour >1cm & no radioiodine planned: Neck US,Tg & TSH follow-up (under surgeons or endocrinologists) suggest 6 monthly Tg & annual neck US for 1st 3 to 5 years. Target TSH: low normal & may need to start thyroxine if TSH > 2 page 7 of 8

6 Who needs Radioiodine after thyroidectomy? Consider the ION trial if eligible 6.1 Papillary thyroid cancer Recommend RI? No if: Tumour <1cm- unifocal or multifocal (no other adverse features) Tumour > 4cm in size, gross extrathyroidal extension or distant mets Recommendations can't be made for or against radioiodine if: 1 4 cm but consider if: any size and any of: - Extrathyroidal extension ( thyroid capsule invasion) - Less favourable histology- (tall cell/ columnar/ diffuse sclerosing/ poorly differentiated) - Involved lymph nodes particularly if large size, many nodes involved or ECS What to do with nodal micromets? Personalised decision making based on other risk factors 6.2 Follicular thyroid cancer Recommend RI? Tumour >4cm in size, gross extrathyroidal extension or distant mets Recommendations can't be made for or against radioiodine if: 1 4 cm but consider if: any size and any of: - Extrathyroidal extension - Widely invasive - Vascular invasion - Involved lymph nodes 6.3 Hurthle cell Consider RI? Tumour >1cm in size page 8 of 8